Objective: Women's risk of obstructive sleep apnea (OSA) increases substantially during and after the menopausal transition, when depression risk is also elevated, raising the possibility that estrogen withdrawal contributes to OSA vulnerability, in turn contributing to mood disturbance. We examined the association between estradiol levels and OSA in depressed peri-and postmenopausal women.
M
enopause is a period of increased risk for the development of sleep problems and mood disturbance. Sleep complaints increase from 12% in women younger than age 44 to 40% in women during the late 40s and early 50s. [1] [2] [3] A common and under-recognized cause of such sleep complaints is obstructive sleep apnea (OSA). OSA is defined by repetitive episodes of complete (apnea) or partial (hypopnea) airway obstruction that are associated with transient oxygen desaturations and brief arousals from sleep. OSA leads to snoring and sleep fragmentation, which in turn can result in excessive daytime sleepiness, cognitive deficits, and mood disturbance. 4 Although often undiagnosed and not treated, 5 it is important to identify and treat OSA because this condition can result in important health problems such as clinical depression, diabetes, cardiovascular disease, heart failure, hypertension, and stroke. 1, 4, 6 Although OSA is 2 to 3 times more prevalent in men than in women before age 50, this sex difference decreases with age because of the increased prevalence of OSA in women during and after the menopausal transition. [6] [7] [8] Women may, however, be less likely to be referred for evaluation and diagnosed with OSA because they can present with a different symptom profile. 4, 5 Women are less likely to have witnessed apneic events and often have symptoms that are less clearly linked to OSA, such as insomnia and depression. 4, 6, 9 For women, the risk of OSA is elevated during pregnancy, in those with polycystic ovarian syndrome, during the late menopausal transition, and in the postmenopause. 5, [10] [11] [12] Other risk factors for OSA in women are increasing age, body mass index (BMI), waist circumference, and anatomical changes in the upper airway. Epidemiologic studies show that, relative to premenopausal women, women in the menopausal transition and recent postmenopause are 3 times more likely to have OSA, [12] [13] [14] after controlling for known OSA risk factors of increasing age and higher BMI. 5 This observation raises the possibility that lower levels of estradiol might contribute to the increased prevalence of OSA during the menopausal transition and early postmenopause.
Women with OSA are more likely than men with OSA to have depression as a presenting symptom. 9 The prevalence of depression is also increased 15, 16 during the menopausal transition and early postmenopause, and depressive symptoms are strongly associated with variability and withdrawal of estradiol. Depression is closely linked with sleep disturbance, including in this midlife population. 17, 18 Therefore, it is plausible that changes in female reproductive hormones underlie the increased vulnerability to both OSA and depression during the menopausal transition and early postmenopause. As such, this preliminary study examines the association between serum estradiol levels and OSA in peri-and early postmenopause women with depressive disorders to test the hypothesis that lower estradiol levels are linked with greater likelihood of OSA in depressed peri-and postmenopausal women.
METHODS
Data for this analysis derive from screening procedures completed as part of two clinical trials 17, 19 focused on 40-to 62-year-old women who (1) were in the menopausal transition and postmenopause, and (2) met criteria for a unipolar depressive disorder. Of the 30 women in this analysis, 23 were screened for one trial, 17 and 7 were screened for the second clinical trial. Participants in this study comprise 20% and 29% of women enrolled in the first and second study, respectively. Details of those studies are available elsewhere. 17 Briefly, women with untreated mild-to-moderate depressive symptoms and no known history of sleep apnea who seemed eligible for the studies provided a blood sample for estradiol and completed a polysomnographic (PSG) study to screen for OSA, which was a key exclusion criterion for the studies. Potential participants were recruited from hospital patients and the community using fliers and approved e-mail circulars. All women who completed these procedures were included in this analysis, regardless of whether they met criteria for OSA or not. Serum estradiol levels in women who had an apnea-hypopnea index (AHI) 15 on the PSG indicating at least moderate OSA 5 were compared against those with an AHI less than 15. All study procedures were approved by the Partners HealthCare Institutional Review Board and completed at Massachusetts General Hospital and Brigham and Women's Hospital between 2005 and 2010 after the women provided written informed consent.
Participants
Eligibility criteria for both of these studies were the same. Women were eligible to participate in these studies if they met the following criteria: (1) 40 to 62 years of age, (2) menopausal transition or postmenopausal, as defined by the STRAW menstrual bleeding criteria, 20 (3) met criteria for a major depressive episode, dysthymia, or a minor depressive episode, (4) were experiencing mild-to-moderate depressive symptoms, as indicated by a score of 15 to 31 on the Montgomery Å sberg Depression Rating Scale (MADRS; range 0-60, higher score worse), 21 and (5) in good general health. Five women who had undergone a hysterectomy without oophorectomy were classified as postmenopausal because they were at least 48 years old, their serum estradiol levels were nondetectable, and their follicle-stimulating hormone levels were more than 50 IU/L. Exclusion criteria included: (1) known sleep disorder, including OSA; (2) psychiatric illness, including severe depression (MADRS score >31), bipolar disorder, and alcohol or substanceuse disorder; (3) current or recent use of centrally active medication including antidepressants, anticonvulsants, or hypnotics; (4) use of systemic hormone medications in the past 3 months; (5) pregnancy; and (6) clinically significant abnormalities in screening laboratory studies. Additional inclusion criteria for one of the studies 17 included the presence of hot flashes and sleep disturbance related to hot flashes.
Measures
Results of a single PSG study obtained for screening purposes was used for this analysis. All screening PSG studies were conducted at Brigham and Women's Hospital Sleep Health Centers in Boston and scored by registered PSG technicians. Standard American Academy of Sleep Medicine-recommended channels were recorded, including EEG, EOG, EMG, respiration (nasal pressure, oral thermistry, oxygen saturation [SaO 2 ], and chest-abdominal motion), EKG, body position, snoring, and bilateral anterior tibialis electromyography. Respiratory events were scored using the Chicago criteria (American Academy of Sleep Medicine 1999). An AHI score 15 indicating at least moderate OSA was used to define the subgroup that had clinically meaningful levels of sleep apnea (n ¼ 13, 43%).
Serum estradiol levels were obtained at the screening visit, which was scheduled within a median of 6 days from the overnight PSG laboratory study. Blood draws were not menstrually timed in women undergoing the menopausal transition. Estradiol was assayed using either immunoassay or liquid chromatography-mass spectrometry. For one study (n ¼ 23), 17 serum samples were analyzed using an automated, random access, microparticle enzyme immunoassay (AxSYM; Abbott Diagnostics, Inc, Abbott Park, IL) with an analytical sensitivity of 20 pg/mL, intra-assay coefficient of variation (CV) 2.1% to 4.5% and interassay CV 6.5% to 9.6%. For the other study (n ¼ 7), serum samples were analyzed using liquid chromatography-mass spectrometry (Mayo Clinic, Rochester, NY) with an analytical sensitivity of 10 pg/mL using an interassay CV of 8.6%. 22 Given these detection limits, serum estradiol was assigned to be 19 pg/mL (n ¼ 8) and 9 pg/mL (n ¼ 5) for assays with analytic sensitivity of 20 and 10 pg/mL, respectively. In sensitivity analyses, estradiol levels less than 20 pg/mL obtained in the study with the more sensitive assay were assigned to 19 pg/mL. The prevalence of OSA was not associated with enrollment in a particular study (P ¼ 0.19).
Statistical analysis
The correlation between the AHI and serum estradiol levels was analyzed using the Spearman correlation coefficient, and the association between estradiol levels and OSA was analyzed using the nonparametric Wilcoxon rank sum test. Logistical regression models were built using OSA as the dependent measure and serum estradiol levels as the primary independent measure. Multivariate models were built to adjust for age and BMI, which are known predictors for OSA. Statistical significance was assumed at the two-sided a ¼ 0.05 level. Parallel approaches were used for secondary analyses using estradiol 19 pg/mL for all women with estradiol levels less than 20 pg/mL. Descriptive data are reported on the proportion of apneic and hypopneic events occurring in rapid eye movement (REM) and non-REM and, similarly, when women were lying supine versus nonsupine among the subgroup of participants with AHI 15, after standardizing to the amount of time spent in REM versus non-REM and supine versus nonsupine.
RESULTS

Participant characteristics
The mean age of all 30 women was 53.7 years (SD 4.4 y). Twenty-three (77%) were postmenopausal (median time from final menstrual period 66 mo) and 7 (23%) women were in the menopausal transition (4 late, 3 early transition). Serum estradiol levels for the group overall (median 24.5, interquartile range [IQR] 19-53 pg/mL) were above the detectable threshold for the assay used in 17 (57%) participants. Undetectable levels were observed in 8 (35%) and 5 (71%) of those in the study with an estradiol threshold of 19 and 9 pg/ mL, respectively. Levels were higher among women in the menopausal transition (median 48, IQR 19-84 pg/mL) than in the postmenopause (median 23, IQR 19-33 pg/mL, P ¼ 0.08). Approximately half of the women were obese (53%, BMI 30 kg/m 2 ), whereas the remainder were overweight (37%, BMI 25-29.9 kg/m 2 ) or of normal weight (10%, BMI 18.5-24.9 kg/m 2 ). 67% of the women included in this study met criteria for major depressive episode, 23% for dysthymia, and 10% for a minor depressive episode. The median AHI was 13.1 (IQR 6.9-19.1).
AHI scores were 15 in 13 (43%) women, whose median AHI was 21.6 (IQR 16.5-33.4). For those without OSA (AHI <15), the median AHI was 7.6 (IQR 4.1-10.2). Table 1 shows study characteristics of the group with and without OSA. Estradiol levels were lower (P ¼ 0.02; Fig. 1 ) in those with OSA (median 19, IQR 9-25 pg/mL) than in those without OSA (median 29, IQR 19-70 pg/mL). Women with OSA were more likely to be overweight or obese than those without OSA (P ¼ 0.01). The groups differed significantly in age (P < 0.001) with women in the OSA group being older than those in the no OSA group. There were no differences between those with and without OSA in race, menopause status, or depressive disorder diagnosis. Median depressive symptom scores on the MADRS did not differ between OSA groups (21, IQR 18-25 vs 20, IQR 17-23, P ¼ 0.61). Continuous variables presented as median and IQR. Categorical data presented as n (%). AHI, apnea-hypopnea index; BMI, body mass index; IQR, interquartile range; OSA, obstructive sleep apnea. a P < 0.05 for those with versus without OSA. b Serum estradiol was assigned to be 19 pg/mL (n ¼ 8) and 9 pg/mL (n ¼ 5) for assays with analytic sensitivity of 20 and 10 pg/mL, respectively. 
GALVAN ET AL
Regression analyses
The odds of meeting criteria for moderate-to-severe OSA was reduced by 5% for every 1 pg/mL increase in the estradiol level (odds ratio [OR] 0.95, 95% CI 0.90-0.99, P ¼ 0.04). Although a greater proportion of postmenopausal women than of those in menopausal transition had OSA (47.8% vs 28.5%, respectively), menopause status was not significantly associated with OSA (P ¼ 0.38). Models restricted to postmenopausal women (n ¼ 23) were consistent, showing a marginal protective association between higher estradiol and odds of OSA (OR 0.95, 95% CI 0.90-1.01, P ¼ 0.11). Estradiol tended to be lower in those with OSA than those without OSA (median estradiol 19 pg/mL vs 26 pg/mL in OSA vs non-OSA, P ¼ 0.08).
AHI was positively correlated with higher BMI (r s ¼ 0.48, P ¼ 0.01) and increasing age (r s ¼ 0.40, P ¼ 0.03). Bivariate logistical regression analyses with moderate-to-severe OSA as the dependent measure revealed that lower estradiol (OR 0.91, 95% CI 0.84-0.99, P ¼ 0.04) and higher BMI (OR 1.46, 95% CI 1.07-1.99, P ¼ 0.02) were significantly associated with OSA. In parallel bivariate logistical regression analyses adjusting for both estradiol and age, age (OR 1.39, 95% CI 1.03-1.89, P ¼ 0.03), but not estradiol levels (OR 0.96, 95% CI 0.91-1.01, P ¼ 0.16), was significantly associated with OSA. Multivariate analyses adjusting simultaneously for estradiol, age, and BMI similarly showed that estradiol levels were not significantly associated with OSA (OR 0.90, 95% CI 0.76-1.05, P ¼ 0.18), whereas older age (OR 2.29, 95% CI 1.09-4.80, P ¼ 0.03) and higher BMI (OR 2.34, 95% CI 1.11-4.95, P ¼ 0.03) were significant correlates.
Exploratory analyses
Results of secondary analyses substituting estradiol 19 pg/mL for all estradiol levels less than 20 pg/mL were consistent with primary analyses (OR 0.95, 95% CI 0.90-1.00, P ¼ 0.055). In additional exploratory analyses, the REM:non-REM AHI ratio was 1.97 and the supine:nonsupine AHI ratio was 1.53, after accounting for the proportion of time spent in REM versus non-REM sleep and in the supine versus nonsupine position, respectively.
DISCUSSION
Results of this preliminary study provide initial evidence that undiagnosed OSA occurs commonly in women with depression who are in the menopausal transition and early postmenopause, and suggest that lower levels of estradiol are associated with moderate-to-severe OSA in this population. The likelihood of having OSA was high (43% OSA prevalence), but not linked with severity of depressive symptoms. Given the cross-sectional analyses and the attenuation of the association after adjustment for age and BMI, we cannot conclude that lower estradiol levels are definitively associated with OSA. Because advancing age is associated with both declining estradiol levels and increasing BMI, our results suggest a need to further consider the roles of reproductive hormones in the context of BMI and age in modulating the vulnerability to OSA that emerges during the late menopausal transition and postmenopause hormonal transition periods. Increasing age might also contribute to susceptibility to OSA through increases in weight gain, upper-airway collapsibility, and sleep fragmentation. Taken together, these preliminary findings suggest that, in midlife women with depression, there is a high prevalence of undiagnosed OSA that is accompanied by lower estradiol levels.
Although withdrawal of reproductive hormones has been hypothesized to contribute to the increased risk of OSA in women during the late menopausal transition and postmenopause, few studies have examined the relationship between estradiol levels and OSA. 23, 24 Results of one small study of women referred to a sleep clinic for suspected OSA showed that estradiol levels were lower in 20 postmenopausal women with OSA as contrasted with 6 postmenopausal women without OSA (mean 12.9 pg/mL vs mean 30.8 pg/mL). 23 Age and BMI were not statistically different between those with and without OSA, but their study results were not statistically adjusted for age or BMI. Our results are consistent with this earlier study, and extend the findings to a distinct population of women who had clinical depression. Our results are also consistent with studies demonstrating an inverse relationship between estradiol and OSA, which is indirectly suggested by reports that postmenopausal women using hormone therapy have a lower prevalence of OSA than those not taking hormone therapy. 13, 25 In contrast, findings from intervention studies using estrogen withdrawal or replacement suggest that there is no clear association between estradiol levels and OSA. 24, [26] [27] [28] [29] Estradiol withdrawal did not induce OSA in a study of 12 healthy premenopausal women evaluated after 5 weeks of hypoestrogenism precipitated by a gonadotropinreleasing hormone agonist. In addition, results of studies administering estrogen therapy to postmenopausal women who have OSA are mixed, with several studies reporting that estrogen with or without progesterone has favorable effects on some, but not all, OSA symptoms and measures, [26] [27] [28] whereas others found no significant improvement in OSA. 24, 27, 28 FIG. 1. Serum estradiol levels in 30 women with depression differed significantly in those with and without obstructive sleep apnea (OSA, defined as AHI 15). Analyses conducted using Wilcoxon rank sum test. AHI, apnea-hypopnea index; OSA, obstructive sleep apnea.
ESTRADIOL AND SLEEP APNEA IN MENOPAUSE
Although results of these intervention studies suggest that the link between estradiol levels and OSA is tenuous, it is notable that the interval in which the estrogen withdrawal or replacement occurred was limited to 5 weeks and a maximum of 24 weeks, respectively. 24, [26] [27] [28] [29] It is plausible that any contribution of reduced estradiol levels to OSA vulnerability may not accrue until there is a substantial period of exposure to hypoestrogenism.
Previous studies have linked OSA and reduced upper-airway activation with reduced levels of both estradiol and progesterone, and several hypotheses about the mechanisms through which reductions in female gonadal steroids are linked with OSA have been proposed. 7 Results of a physiologic study conducted in women without OSA showed that activation of the pharyngeal dilating genioglossal muscle is lowest in postmenopausal women and lower in the midfollicular than the midluteal phase among premenopausal women, 30 which could render the pharyngeal airway more vulnerable to collapse during sleep. In contrast, upper-airway resistance was not influenced by menopause status or gonadal steroid levels. 30 Although a limitation of our study was that progesterone was not measured, progesterone levels are exceedingly low in postmenopausal hypoestrogenic women due to anovulation. It is also plausible that estradiol and progesterone may affect ventilatory control stability or the arousal threshold, but this hypothesis was not examined.
Like other populations of midlife women, our peri-/postmenopausal study sample has a greater proportion of OSA events during REM than do men. 31, 32 We also observed our midlife female population to have a disproportionately greater number of apneic and hypopneic events in the supine position, consistent with studies in postmenopausal women and in men, 32 and higher than that in younger women. 33 Our findings add to the literature showing that, like men, postmenopausal women with OSA are more position sensitive and have more apneic events lying on their back.
We identified moderate-to-severe OSA in 43% of midlife women seeking treatment for an episode of depression. This prevalence estimate is consistent with that in other clinicbased estimates in depressed individuals (median 48% prevalence, range 0%-66%). 34 We focused on moderate-to-severe OSA because this OSA threshold has been most strongly associated with important health outcomes. In addition, limited statistical power precluded use of a more liberal threshold that included women with much milder OSA (AHI 5; n ¼ 24, 80% of sample). Levels of depressive symptoms did not differ between those with and without OSA, but our study design limited our ability to discriminate because the MADRS range was restricted to 15 to 31 for study eligibility, limiting our ability to assess the association with the full spectrum of depressive symptoms. The high prevalence of OSA, however, highlights the importance of OSA screening in peri-/postmenopausal women with depression who present with depression during midlife, particularly those who are obese or overweight. Approximately half of our study population was obese. Higher BMI and body fat in the neck region specifically are linked with OSA in women. 35 Higher BMI and body fat are, however, linked with higher estradiol levels in postmenopausal women, [36] [37] [38] highlighting the complex relationship of OSA with BMI and estradiol levels that warrant further exploration.
Although limited by small sample size and a single crosssectional measure of estradiol, this study provides preliminary evidence warranting further investigation in women because of the potential to identify women susceptible to both OSA and depression episodes during the menopausal transition and postmenopause. The largely obese study population might also limit generalizability of our findings to the women with a lower mean BMI. The cumulative detrimental effects of OSA and depression, often in combination with increasing BMI, can lead to sleepiness, lethargy, and social withdrawal that perpetuates poor health and well-being in aging women.
CONCLUSIONS
These preliminary results suggest that risk factors for OSA in depressed women during the menopausal transition and postmenopause may include lower estradiol levels as well as age and BMI. Although our study was not sufficiently large to disentangle the independent contributions of these factors, our findings raise the possibility that estradiol withdrawal associated with increasing age during the menopausal transition and postmenopause may influence the predisposition to OSA in women. Women are more likely to experience depression in general and to have mood disturbance as a presenting symptom of an undiagnosed OSA, emphasizing the importance of screening for OSA in midlife women with depression who may or may not have other OSA features (eg, sleepiness) or that is nonresponsive to traditional interventions for depression. These studies have important implications for the diagnosis and treatment of comorbid sleep disorders in midlife women with depression.
